Silo Pharma, Inc.

SILO

US82711P2011

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 16:00:00 2024-05-31 EDT			5-day change	1st Jan Change
2.08 ^USD	+4.00%		+8.33%	+44.44%

05-21	Silo Pharma, Inc. Announces Positive Results from Study for Depression Treatment, Remission, and Relapse Prevention	CI
05-13	Silo Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Point Capital, Inc. will Change its Name to Uppercut Brands, Inc

July 22, 2019 at 12:00 am

Effective July 22, 2019, Point Capital, Inc. will change its name to Uppercut Brands, Inc.

Latest news about Silo Pharma, Inc.

Silo Pharma, Inc. Announces Positive Results from Study for Depression Treatment, Remission, and Relapse Prevention	05-21	CI
Silo Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-13	CI
Silo Pharma, Inc. Announces Positive Results for Intranasal PTSD Treatment	04-23	CI
Silo Pharma Says It Exercised Option to License Alzheimer's Therapeutic From Columbia University	04-10	MT
Tranche Update on Silo Pharma, Inc.'s Equity Buyback Plan announced on January 31, 2023.	04-05	CI
Silo Pharma, Inc.'s Equity Buyback Plan Extended till March 31, 2024.	04-03	CI
Tranche Update on Silo Pharma, Inc.'s Equity Buyback Plan announced on January 31, 2023.	03-25	CI
Silo Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-25	CI
Silo Pharma, Inc. Exercises Option for Exclusive License Agreement for First-In-Class PTSD and Stress-Induced Anxiety Therapeutic	03-20	CI
Silo Pharma, Inc. Files Patent for Groundbreaking Ketamine Implant Therapeutic to Target Fibromyalgia and Chronic Pain	03-18	CI
Silo Pharma?s SP-26 Ketamine Implant Demonstrates Successful Drug Delivery	02-14	CI
Silo Pharma, Inc. Announces Pipeline Prioritization for 2024 Targeting Mental Health, Chronic Pain, and Neurology	02-01	CI
Silo Pharma Announces Positive Results in Alzheimer?s Disease Study	01-24	CI
Silo Pharma, Inc.'s Equity Buyback Plan Extended till March 31, 2024.	01-08	CI
Silo Pharma Successfully Completes First Phase of Dose-Ranging Study of SPC-15 an Intranasal Treatment for PTSD	01-04	CI
Silo Pharma, Partner Receive Regulatory Approval to Develop Ketamine Implant for Fibromyalgia Treatment	12-28	MT
Silo Pharma and Partner Receive Regulatory Approval to Begin Development of Ketamine Implant for Fibromyalgia	12-28	CI
Top Premarket Decliners	11-20	MT
Top Premarket Decliners	11-17	MT
Tranche Update on Silo Pharma, Inc.'s Equity Buyback Plan announced on January 31, 2023.	11-13	CI
Silo Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-13	CI
Silo Pharma, Inc. to Initiate Dose-Ranging Study of Novel Intranasal Therapeutic SPC-15 for the Treatment of PTSD	11-08	CI
Silo Pharma?s SPU-21 Peptide Shows Positive Results Against Rheumatoid Arthritis	23-10-16	CI
Silo Pharma, Inc. Announces Positive Data on SPC-15 for PTSD and Prepares to File Pre-Investigational New Drug Application with FDA	23-09-20	CI
Silo Pharma, Inc. Initiates Feasibility Study of SPC-15 Novel Intranasal Formulation for PTSD	23-09-12	CI

Silo Pharma, Inc. is a developmental stage biopharmaceutical company. The Company is focused on developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It is engaged in acquiring and/or developing intellectual property or technology rights from universities and researchers to treat rare diseases, including the use of psychedelic drugs, such as psilocybin, and the potential benefits they may have in certain cases involving depression, mental health issues and neurological disorders. The Companyâs lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. Its SP-26 is a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. Its two preclinical programs are SPC-14, an intranasal compound for the treatment of Alzheimerâs disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS).

Sector

Pharmaceuticals

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
SILO PHARMA, INC.	+44.44%	5.91M
CSL LIMITED	-2.29%	89.87B
SAMSUNG BIOLOGICS CO.,LTD.	-3.95%	37.57B
BIOGEN INC.	-13.07%	32.75B
UCB	+63.05%	26.47B
BIOMARIN PHARMACEUTICAL INC.	-22.14%	14.25B
INCYTE CORPORATION	-7.96%	12.99B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-9.33%	11.93B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-46.33%	10.84B
SWEDISH ORPHAN BIOVITRUM AB	+5.77%	9.11B

Biopharmaceuticals

Silo Pharma, Inc.

Equities

SILO

US82711P2011

Pharmaceuticals

Point Capital, Inc. will Change its Name to Uppercut Brands, Inc

Latest news about Silo Pharma, Inc.

Chart Silo Pharma, Inc.

Company Profile

Income Statement Evolution

Annual profits - Rate of surprise

Sector Biopharmaceuticals